<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that, further to the Company’s press release dated April 21, 2021, the Company’s team of scientists at its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has received positive results and believes that replication of its proprietary recombinant production system (the “Production System”), currently proven and utilized for the production of psilocybin, will result in successful production of API-Grade N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)).
...read full article on GlobeNewsWire
